Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Cancer Res. 2009 Jan 13;69(3):828–835. doi: 10.1158/0008-5472.CAN-08-2588

Table 1.

Site-specific brain metastasis produced by B16-BL6 and K-1735 C4 melanoma cells in syngeneic and B6C3F1 cross mice

C57BL/6
B6C3F1
Cell line Leptomeninges, ventricles Parenchyma Leptomeninges, ventricles Parenchyma
B16-BL6 14/14 0/14 4/4 0/4
B16-BL6/vector control 15/15 0/15 5/5 0/5
B16-BL6/TGF-β2 OE 19/19 5/19* 5/5 1/5*
C3H/HeN
B6C3F1
Cell line Leptomeninges, ventricles Parenchyma† Leptomeninges, ventricles Parenchyma
K-1735 C4 0/20 20/20 0/5 5/5
K-1735 C4/shRNA control 0/19 19/19 0/5 5/5
K-1735 C4/TGF-β2 shRNA 0/20 17/20‡ 0/4 4/4
*

B16-BL6 cells overexpressing the TGF-β2 cytokine produced microscopic tumor lesions in the brain parenchyma.

†

K-1735 C4 cells and derivative cells produced grossly visible tumors in the brain parenchyma. The production of parenchymal lesions was significantly delayed in mice injected with K-1735 C4/TGF-β2 shRNA cells.

‡

Three mice killed 24 d after tumor injection had no visible brain parenchymal lesions.